

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hansoh Pharmaceutical Group Company Limited**

**翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 3692)**

### **VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE RESTRICTED SHARE UNIT SCHEME**

This announcement is made by Hansoh Pharmaceutical Group Company Limited (the “**Company**”) on a voluntary basis.

Reference is made to the restricted share unit scheme (the “**Scheme**”) conditionally approved and adopted by the Company on May 27, 2019, a summary of the principal terms of the Scheme is set out in the section headed “Statutory and General Information – D. Post-IPO RSU Scheme” in Appendix IV of the prospectus of the Company dated May 31, 2019 (the “**Prospectus**”). Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as ascribed to them in the Prospectus.

The Company was informed by the RSU Trustee that it had purchased an aggregate of 1,750,000 Shares (the “**Share Purchase**”) on the market for the purpose of the Scheme in April 2023. Details of the Share Purchase and the latest information about the Shares held by the RSU Trustee are as follows:

Trade date(s):	April 4, 2023 to April 27, 2023
Settlement date(s):	April 11, 2023 to May 2, 2023
Total number of Shares purchased:	1,750,000 Shares
Percentage of the Shares purchased to the total number of issued Shares as at the date of this announcement:	Approximately 0.03%

Average consideration per Share (excluding all related expenses, including but not limited to transaction levy, brokerage, tax): Approximately HK\$13.8075

Total consideration of Shares purchased (excluding all related expenses, including but not limited to transaction levy, brokerage, tax): HK\$24,163,097

Balance of Shares held by the RSU Trustee:

– *Prior to the Share Purchase* 3,103,660 Shares

– *Immediately after the Share Purchase* <sup>Note</sup> 13,323,180 Shares

*Note:* The balance has been arrived at after taking into consideration of the allotment and issue of 11,000,000 shares of the Company on April 21, 2023 to the RSU Trustee pursuant to the Scheme and the vesting of certain RSUs during the month.

Subject to and in compliance with the requirements of the Listing Rules, the Board will from time to time review and determine at its absolute discretion such number of the RSU(s) to be awarded to the Selected Person(s) with such vesting conditions as it may deem appropriate and the number of Shares to be further purchased from the market under the Scheme.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, April 28, 2023

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*